8-KOther Events

DEXCOM INC 8-K Report, Corporate Update (Jul 1, 2021)

Filed July 1, 2021For Securities:DXCM

Summary

DexCom, Inc. (DXCM) has initiated litigation against Abbott Diabetes Care, Inc. (Abbott) on June 30, 2021, alleging infringement of its patents related to continuous glucose monitoring (CGM) technology. This action follows the expiration of a covenant not to sue that was part of a 2014 settlement agreement between the two companies, which expired on March 31, 2021. DexCom is seeking damages and injunctive relief, asserting that Abbott's Libre products infringe on its proprietary CGM patents. This legal action signifies DexCom's proactive stance in defending its intellectual property in the competitive diabetes care market.

Key Highlights

  • 1DexCom (DXCM) has filed a lawsuit against Abbott Diabetes Care (Abbott) for patent infringement.
  • 2The litigation concerns DexCom's patents for continuous glucose monitoring (CGM) technology.
  • 3Abbott's Libre products are specifically cited as infringing DexCom's patents.
  • 4The lawsuit was filed following the expiration of a prior settlement's 'covenant not to sue' on March 31, 2021.
  • 5DexCom is seeking both monetary damages and injunctive relief from the court.
  • 6This move indicates DexCom's commitment to protecting its intellectual property in the CGM market.

Frequently Asked Questions

DexCom has filed the lawsuit alleging that Abbott's Libre products infringe on certain of DexCom's patents related to its proprietary continuous glucose monitoring (CGM) technology.

The lawsuit was initiated because a 'covenant not to sue' between DexCom and Abbott, part of a 2014 settlement agreement, expired on March 31, 2021. This expiration allowed DexCom to pursue legal action to protect its intellectual property.

DexCom is seeking both damages, which would be monetary compensation for the alleged infringement, and injunctive relief, which would aim to stop Abbott from continuing to infringe on their patents.

The filing of a lawsuit itself does not directly impact current operations or sales. However, the outcome of the litigation could potentially affect market dynamics and future sales for both companies, especially concerning products utilizing CGM technology.